New UK Biosimilars Pathway Suffers Setback
MHRA Consultation Review Delayed Due To ‘Intense COVID-19 Activities’
Executive Summary
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
You may also be interested in...
UK Could Become ‘World Leader’ On Biosimilar Regulation
The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard.
UK Could Become ‘World Leader’ On Biosimilar Regulation
The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard earlier today.
UK First To Authorize Pfizer/BioNTech COVID-19 Vaccine
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.